Table F- 12Saxagliptin compared with placebo, as add-on therapy to metformin

Domains pertaining to strength of evidenceMagnitude of effectStrength of evidence
Number of Studies; # of SubjectsRisk of Bias (Design/Quality)ConsistencyDirectnessPrecisionSummary Effect Size (95% Confidence Interval)High, Moderate, Low, Insufficient
HbA1c
1; 743Medium
RCT/Fair
Unknown (single study)IndirectPreciseGreater reduction with saxagliptin (between group difference −0.72 to −0.82%)Low
Weight change
1; 743Medium
RCT/Fair
Unknown (single study)IndirectPreciseGreater reduction with saxagliptin 2.5 mg, but not saxagliptin 5 mg, compared with placeboLow

From: Appendix F, Strength of evidence

Cover of Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations
Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations: Final Original Report [Internet].
Jonas D, Van Scoyoc E, Gerrald K, et al.
Portland (OR): Oregon Health & Science University; 2011 Feb.
Copyright © 2011, Oregon Health & Science University.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.